Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015 (2015), Article ID 801348, 13 pages
http://dx.doi.org/10.1155/2015/801348
Review Article

Present and Future in the Treatment of Diabetic Kidney Disease

1Nephrology Unit, Hospital Universitario de Guadalajara, Spain
2Nephrology Unit, Hospital Universitari Arnau de Vilanova, Lleida, Spain
3Medicine and Medicine Specialities Department, Universidad de Alcalá (UAH), Madrid, Spain

Received 8 January 2015; Revised 26 March 2015; Accepted 27 March 2015

Academic Editor: Daisuke Koya

Copyright © 2015 Borja Quiroga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Centers for Disease Control and Prevention, Diabetes Report Card 2012, Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga, USA, 2012, http://www.cdc.gov/diabetes/pubs/pdf/diabetesreportcard.pdf.
  2. United States Renal Data System, 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, USA, 2014, http://www.usrds.org/2014/view/Default.aspx.
  3. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates of the prevalence of diabetes for 2010 and 2030,” Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. A. X. Garg, B. A. Kiberd, W. F. Clark, R. B. Haynes, and C. M. Clase, “Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III,” Kidney International, vol. 61, no. 6, pp. 2165–2175, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Retnakaran, C. A. Cull, K. I. Thorne, A. I. Adler, R. R. Holman, and UKPDS Study Group, “Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74,” Diabetes, vol. 55, no. 6, pp. 1832–1839, 2006. View at Google Scholar
  6. M. E. Molitch, M. Steffes, W. Sun et al., “Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study,” Diabetes Care, vol. 33, no. 7, pp. 1536–1543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. S. Levey, D. Cattran, A. Friedman et al., “Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration,” American Journal of Kidney Diseases, vol. 54, no. 2, pp. 205–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Thompson, “Proteinuria as a surrogate end point-more data are needed,” Nature Reviews Nephrology, vol. 8, no. 5, pp. 306–309, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. G. L. Bakris, “Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus,” Mayo Clinic Proceedings, vol. 86, no. 5, pp. 444–456, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. DCCT/EDIC Research Group, “Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial,” Kidney International, vol. 47, no. 6, pp. 1703–1720, 1995. View at Publisher · View at Google Scholar
  11. DCCT/EDIC Research Group, “Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The diabetes control and complications trial/epidemiology of diabetes interventions and complications research group,” The New England Journal of Medicine, vol. 342, no. 6, pp. 381–389, 2000. View at Google Scholar
  12. ADVANCE Collaborative Group, A. Patel, S. MacMahon et al., “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2560–2572, 2008. View at Publisher · View at Google Scholar
  13. The DCCT/EDIC Research Group, I. H. de Boer, W. Sun et al., “Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes,” The New England Journal of Medicine, vol. 365, no. 25, pp. 2366–2376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Perkovic, H. L. Heerspink, J. Chalmers et al., “Intensive glucose control improves kidney outcomes in patients with type 2 diabetes,” Kidney International, vol. 83, no. 3, pp. 517–523, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Daniels, S. N. Dubose, D. M. Maahs et al., “Factors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D exchange clinic registry,” Diabetes Care, vol. 36, no. 9, pp. 2639–2645, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. I. H. de Boer and DCCT/EDIC Research Group, “Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study,” Diabetes Care, vol. 37, no. 1, pp. 24–30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. American Diabetes Association, “Standards of medical care in diabetes—2015,” Diabetes Care, vol. 38, supplement 1, pp. S4–S93, 2015. View at Publisher · View at Google Scholar
  18. KDOQI, “KDOQI clinical practice guideline for diabetes and CKD: 2012 update,” American Journal of Kidney Diseases, vol. 60, no. 5, pp. 850–886, 2012. View at Publisher · View at Google Scholar
  19. P.-H. Groop, M. E. Cooper, V. Perkovic, A. Emser, H.-J. Woerle, and M. von Eynatten, “Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction,” Diabetes Care, vol. 36, no. 11, pp. 3460–3468, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Fujita, H. Taniai, H. Murayama et al., “DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy,” Endocrine Journal, vol. 61, no. 2, pp. 159–166, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Daniels, S. N. DuBose, D. M. Maahs et al., “KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease,” American Journal of Kidney Diseases, vol. 49, supplement 2, no. 2, pp. S12–S154, 2007. View at Publisher · View at Google Scholar
  22. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group, “KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease,” Kidney International Supplements, vol. 2, pp. 337–414, 2012. View at Publisher · View at Google Scholar
  23. W. C. Cushman, G. W. Evans, R. P. Byington et al., “Effects of intensive blood-pressure control in type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 362, no. 17, pp. 1575–1585, 2010. View at Publisher · View at Google Scholar
  24. H. Haller, S. Ito, J. L. Izzo Jr. et al., “Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes,” The New England Journal of Medicine, vol. 364, no. 10, pp. 907–917, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Eknoyan, “Obesity, diabetes, and chronic kidney disease,” Current Diabetes Reports, vol. 7, no. 6, pp. 449–453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. F. Briffa, A. J. Mcainch, P. Poronnik, and D. H. Hryciw, “Adipokines as a link between obesity and chronic kidney disease,” The American Journal of Physiology—Renal Physiology, vol. 305, no. 12, pp. F1629–F1636, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. M. C. E. Rossi, A. Nicolucci, F. Pellegrini et al., “Obesity and changes in urine albumin/creatinine ratio in patients with type 2 diabetes: the DEMAND Study,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 20, no. 2, pp. 110–116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. N. Friedman, M. Chambers, L. M. Kamendulis, and J. Temmerman, “Short-term changes after a weight reduction intervention in advanced diabetic nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 11, pp. 1892–1898, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Morales, M. A. Valero, M. León, E. Hernández, and M. Praga, “Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies,” American Journal of Kidney Diseases, vol. 41, no. 2, pp. 319–327, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. K. J. Neff, A. H. Frankel, F. W. K. Tam, D. M. Sadlier, C. Godson, and C. W. le Roux, “The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation,” Nephrology Dialysis Transplantation, vol. 28, supplement 4, pp. 73–82, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. B. L. Kasiske, J. D. A. Lakatua, J. Z. Ma, and T. A. Louis, “A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function,” American Journal of Kidney Diseases, vol. 31, no. 6, pp. 954–961, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. L. T. J. Pijls, H. de Vries, A. J. M. Donker, and J. T. M. van Eijk, “The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial,” Nephrology Dialysis Transplantation, vol. 14, no. 6, pp. 1445–1453, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. H. P. Hansen, E. Tauber-Lassen, B. R. Jensen, and H.-H. Parving, “Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy,” Kidney International, vol. 62, no. 1, pp. 220–228, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Cignarelli, O. Lamacchia, S. di Paolo, and L. Gesualdo, “Cigarette smoking and kidney dysfunction in diabetes mellitus,” Journal of Nephrology, vol. 21, no. 2, pp. 180–189, 2008. View at Google Scholar · View at Scopus
  35. T. Chuahirun, J. Simoni, C. Hudson et al., “Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes,” American Journal of the Medical Sciences, vol. 327, no. 2, pp. 57–67, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Phisitkul, K. Hegazy, T. Chuahirun et al., “Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy,” The American Journal of the Medical Sciences, vol. 335, no. 4, pp. 284–291, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. D. de Zeeuw, G. Remuzzi, H.-H. Parving et al., “Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL,” Kidney International, vol. 65, no. 6, pp. 2309–2320, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. E. J. Lewis, L. G. Hunsicker, W. R. Clarke et al., “Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes,” The New England Journal of Medicine, vol. 345, no. 12, pp. 851–860, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Viberti, C. E. Mogensen, L. C. Groop, and J. F. Pauls, “Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group,” Journal of the American Medical Association, vol. 271, no. 4, pp. 275–279, 1994. View at Publisher · View at Google Scholar · View at Scopus
  40. L. M. B. Laffel, J. B. McGill, and D. J. Gans, “The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria,” The American Journal of Medicine, vol. 99, no. 5, pp. 497–504, 1995. View at Publisher · View at Google Scholar · View at Scopus
  41. L. F. Fried, N. Emanuele, J. H. Zhang et al., “Combined angiotensin inhibition for the treatment of diabetic nephropathy,” The New England Journal of Medicine, vol. 369, no. 20, pp. 1892–1903, 2013. View at Publisher · View at Google Scholar
  42. G. Fernandez Juarez, J. Luño, V. Barrio et al., “Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial,” American Journal of Kidney Diseases, vol. 61, no. 2, pp. 211–218, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. ONTARGET Investigators, S. Yusuf, K. K. Teo et al., “Telmisartan, ramipril, or both in patients at high risk for vascular events,” The New England Journal of Medicine, vol. 358, no. 15, pp. 1547–1559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Tylicki, A. Jakubowska, S. Lizakowski, D. Swietlik, and B. Rutkowski, “Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study,” Journal of the Renin-Angiotensin-Aldosterone System, 2014. View at Publisher · View at Google Scholar
  45. H.-H. Parving, B. M. Brenner, J. J. V. McMurray et al., “Cardiorenal end points in a trial of aliskiren for type 2 diabetes,” The New England Journal of Medicine, vol. 367, no. 23, pp. 2204–2213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. H.-H. Parving, F. Persson, J. B. Lewis, E. J. Lewis, and N. K. Hollenberg, “Aliskiren combined with losartan in type 2 diabetes and nephropathy,” The New England Journal of Medicine, vol. 358, no. 23, pp. 2433–2446, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Sato, K. Hayashi, M. Naruse, and T. Saruta, “Effectiveness of aldosterone blockade in patients with diabetic nephropathy,” Hypertension, vol. 41, no. 1, pp. 64–68, 2003. View at Publisher · View at Google Scholar
  48. A. Esteghamati, S. Noshad, S. Jarrah, M. Mousavizadeh, S. H. Khoee, and M. Nakhjavani, “Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial,” Nephrology Dialysis Transplantation, vol. 28, no. 11, pp. 2823–2833, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Epstein, G. H. Williams, M. Weinberger et al., “Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes,” Clinical journal of the American Society of Nephrology, vol. 1, no. 5, pp. 940–951, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Susantitaphong, K. Sewaralthahab, E. M. Balk, S. Eiam-Ong, N. E. Madias, and B. L. Jaber, “Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis,” American Journal of Hypertension, vol. 26, no. 3, pp. 424–441, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. F. F. Hou, D. Xie, X. Zhang et al., “Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency,” Journal of the American Society of Nephrology, vol. 18, no. 6, pp. 1889–1898, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Ruggenenti, A. Fassi, A. P. Ilieva et al., “Preventing microalbuminuria in type 2 diabetes,” The New England Journal of Medicine, vol. 351, no. 19, pp. 1941–1951, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Lv, V. Perkovic, C. V. Foote, M. E. Craig, J. C. Craig, and G. F. M. Strippoli, “Antihypertensive agents for preventing diabetic kidney disease.,” Cochrane Database of Systematic Reviews, no. 12, Article ID CD004136, 2012. View at Google Scholar · View at Scopus
  54. M. G. Saklayen, L. K. Gyebi, J. Tasosa, and J. Yap, “Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial,” Journal of Investigative Medicine, vol. 56, no. 4, pp. 714–719, 2008. View at Google Scholar · View at Scopus
  55. M. B. Davidson, A. Wong, A. H. Hamrahian, M. Stevens, and E. S. Siraj, “Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors,” Endocrine Practice, vol. 14, no. 8, pp. 985–992, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. U. F. Mehdi, B. Adams-Huet, P. Raskin, G. L. Vega, and R. D. Toto, “Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2641–2650, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Bianchi, R. Bigazzi, and V. M. Campese, “Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease,” Kidney International, vol. 70, no. 12, pp. 2116–2123, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Morales, V. G. Millet, J. Rojas-Rivera et al., “Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases,” Nephrology Dialysis Transplantation, vol. 28, no. 2, pp. 405–412, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. B. Pitt, F. Zannad, W. J. Remme et al., “The effect of spironolactone on morbidity and mortality in patients with severe heart failure,” The New England Journal of Medicine, vol. 341, no. 10, pp. 709–717, 1999. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Fernandez-Fernandez, A. Ortiz, C. Gomez-Guerrero, and J. Egido, “Therapeutic approaches to diabetic nephropathy—beyond the RAS,” Nature Reviews Nephrology, vol. 10, no. 6, pp. 325–346, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Zheng, S. A. Whitman, W. Wu et al., “Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy,” Diabetes, vol. 60, no. 11, pp. 3055–3066, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Yoh, A. Hirayama, K. Ishizaki et al., “Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice,” Genes to Cells, vol. 13, no. 11, pp. 1159–1170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. P. E. Pergola, P. Raskin, R. D. Toto et al., “Bardoxolone methyl and kidney function in CKD with type 2 diabetes,” The New England Journal of Medicine, vol. 365, no. 4, pp. 327–336, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. D. de Zeeuw, T. Akizawa, P. Audhya et al., “Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease,” The New England Journal of Medicine, vol. 369, no. 26, pp. 2492–2503, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. S. M. Tan, A. Sharma, N. Stefanovic et al., “Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease,” Diabetes, vol. 63, no. 9, pp. 3091–3103, 2014. View at Publisher · View at Google Scholar
  66. G. Fernández-Juárez, J. Luño, V. Barrio et al., “25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 11, pp. 1870–1876, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. D. L. Andress, “Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation,” Kidney International, vol. 69, no. 1, pp. 33–43, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Agarwal, M. Acharya, J. Tian et al., “Antiproteinuric effect of oral paricalcitol in chronic kidney disease,” Kidney International, vol. 68, no. 6, pp. 2823–2828, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. D. de Zeeuw, R. Agarwal, M. Amdahl et al., “Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial,” The Lancet, vol. 376, no. 9752, pp. 1543–1551, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. H. J. Lambers Heerspink, R. Agarwal, D. W. Coyne et al., “The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics,” The American Journal of Nephrology, vol. 30, no. 3, pp. 280–286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. Z. Eren, M. Y. Günal, E. A. Bakir et al., “Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats,” Kidney and Blood Pressure Research, vol. 39, no. 6, pp. 581–590, 2014. View at Publisher · View at Google Scholar
  72. M. H. de Borst, R. Hajhosseiny, H. Tamez, J. Wenger, R. Thadhani, and D. J. A. Goldsmith, “Active vitamin D treatment for reduction of residual proteinuria: a systematic review,” Journal of the American Society of Nephrology, vol. 24, no. 11, pp. 1863–1871, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. N. K. Agrawal and S. Kant, “Targeting inflammation in diabetes: newer therapeutic options,” World Journal of Diabetes, vol. 5, no. 5, pp. 697–710, 2014. View at Publisher · View at Google Scholar
  74. M. Rodríguez-Morán, G. González-González, M. V. Bermúdez-Barba et al., “Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria—a double-blind, placebo-controlled randomized trial,” Clinical Nephrology, vol. 66, no. 1, pp. 3–10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. J. F. Navarro-González, C. Mora-Fernández, M. Muros de Fuentes et al., “Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial,” Journal of the American Society of Nephrology, vol. 26, no. 1, pp. 220–229, 2015. View at Publisher · View at Google Scholar
  76. M. Goicoechea, S. G. de Vinuesa, B. Quiroga et al., “Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial,” Journal of Nephrology, vol. 25, no. 6, pp. 969–975, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. F. P. Brouwers, F. W. Asselbergs, H. L. Hillege et al., “Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT),” The American Heart Journal, vol. 161, no. 6, pp. 1171–1178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. S. J. Shah, D. D. Waters, P. Barter et al., “Intensive lipid-lowering with atorvastatin for secondaryprevention in patients after coronary artery bypass surgery,” Journal of the American College of Cardiology, vol. 51, no. 20, pp. 1938–1943, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. W. Lieberthal and J. S. Levine, “The role of the mammalian target of rapamycin (mTOR) in renal disease,” Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2493–2502, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. A. H. Hopper, H. Tindall, and J. A. Davies, “Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 4, no. 2, pp. 140–143, 1989. View at Google Scholar · View at Scopus
  81. J. Rodriguez-Vita, M. Ruiz-Ortega, M. Rupérez et al., “Endothelin-1, via ETA receptor and independently of transforming growth factor-β, increases the connective tissue growth factor in vascular smooth muscle cells,” Circulation Research, vol. 97, no. 2, pp. 125–134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. D. E. Kohan and D. M. Pollock, “Endothelin antagonists for diabetic and non-diabetic chronic kidney disease,” British Journal of Clinical Pharmacology, vol. 76, no. 4, pp. 573–579, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. D. Gómez-Garre, R. Largo, X.-H. Liu et al., “An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis,” Kidney International, vol. 50, no. 3, pp. 962–972, 1996. View at Publisher · View at Google Scholar · View at Scopus
  84. D. E. Kohan, J. G. Cleland, L. J. Rubin, D. Theodorescu, and M. Barton, “Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?” Life Sciences, vol. 91, no. 13-14, pp. 528–539, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. J. F. E. Mann, D. Green, K. Jamerson et al., “Avosentan for overt diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 21, no. 3, pp. 527–535, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. D. L. Andress, B. Coll, Y. Pritchett, J. Brennan, M. Molitch, and D. E. Kohan, “Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD),” Life Sciences, vol. 91, no. 13-14, pp. 739–742, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. K. Winiarska, K. Szymanski, P. Gorniak, M. Dudziak, and J. Bryla, “Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits,” Biochimie, vol. 91, no. 2, pp. 261–270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. G. G. Wang, X. H. Lu, W. Li, X. Zhao, and C. Zhang, “Protective effects of luteolin on diabetic nephropathy in STZ-induced diabetic rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 323171, 7 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Bhattacharya, P. Manna, R. Gachhui, and P. C. Sil, “D-Saccharic acid 1,4-lactone protects diabetic rat kidney by ameliorating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via NF-κB and PKC signaling,” Toxicology and Applied Pharmacology, vol. 267, no. 1, pp. 16–29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. K. Khazim, Y. Gorin, R. C. Cavaglieri, H. E. Abboud, and P. Fanti, “The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo,” American Journal of Physiology—Renal Physiology, vol. 305, no. 5, pp. F691–F700, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. J. F. Ndisang and A. Jadhav, “Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: role of the heme oxygenase/atrial natriuretic peptide/adiponectin axis,” Endocrinology, vol. 155, no. 1, pp. 215–229, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. Z. Sun, Q. Fu, L. Cao, W. Jin, L. Cheng, and Z. Li, “Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials,” PLoS ONE, vol. 8, no. 1, Article ID e55124, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. M. K. Fallahzadeh, B. Dormanesh, M. M. Sagheb et al., “Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial,” American Journal of Kidney Diseases, vol. 60, no. 6, pp. 896–903, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. S. R. Hashemi, H. Noshad, A. Tabrizi et al., “Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus,” Iranian Journal of Kidney Diseases, vol. 6, no. 1, pp. 39–43, 2012. View at Google Scholar · View at Scopus
  95. K. Endo, A. Saiki, T. Yamaguchi et al., “Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura Study,” Journal of Atherosclerosis and Thrombosis, vol. 20, no. 5, pp. 494–502, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. Y.-P. Siu, K.-T. Leung, M. K.-H. Tong, and T.-H. Kwan, “Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level,” American Journal of Kidney Diseases, vol. 47, no. 1, pp. 51–59, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Goicoechea, S. G. de Vinuesa, U. Verdalles et al., “Effect of allopurinol in chronic kidney disease progression and cardiovascular risk,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1388–1393, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. D. M. Maahs, L. Caramori, D. Z. I. Cherney et al., “Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study,” Current Diabetes Reports, vol. 13, no. 4, pp. 550–559, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. T. Hosoya, K. Kimura, S. Itoh et al., “The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study,” Trials, vol. 15, no. 1, article 26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Budhiraja and J. Singh, “Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications,” Fundamental and Clinical Pharmacology, vol. 22, no. 3, pp. 231–240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. D. Bansal, Y. Badhan, K. Gudala, and F. Schifano, “Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials,” Diabetes & Metabolism Journal, vol. 37, no. 5, pp. 375–384, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. M. J. Sheetz, L. P. Aiello, M. D. Davis et al., “The effect of the Oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies,” Investigative Ophthalmology and Visual Science, vol. 54, no. 3, pp. 1750–1757, 2013. View at Publisher · View at Google Scholar · View at Scopus
  103. K. R. Tuttle, J. B. McGill, D. J. Haney, T. E. Lin, and P. W. Anderson, “Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 4, pp. 631–636, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. K. R. Tuttle, G. L. Bakris, R. D. Toto, J. B. McGill, K. Hu, and P. W. Anderson, “The effect of ruboxistaurin on nephropathy in type 2 diabetes,” Diabetes Care, vol. 28, no. 11, pp. 2686–2690, 2005. View at Publisher · View at Google Scholar · View at Scopus
  105. K. R. Tuttle, J. B. McGill, E. J. Bastyr III, K. K. Poi, N. Shahri, and P. W. Anderson, “Effect of ruboxistaurin on albuminuria and estimated GFR in people with diabetic peripheral neuropathy: results from a randomized trial,” American Journal of Kidney Diseases, vol. 65, no. 4, pp. 634–636, 2015. View at Publisher · View at Google Scholar
  106. M. Lassila, K. Jandeleit-Dahm, K. K. Seah et al., “Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice,” Journal of the American Society of Nephrology, vol. 16, no. 2, pp. 367–373, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Iyoda, T. Shibata, Y. Hirai, Y. Kuno, and T. Akizawa, “Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease,” Journal of the American Society of Nephrology, vol. 22, no. 8, pp. 1486–1496, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. M. J. Kim and Y. Lim, “Protective effect of short-term genistein supplementation on the early stage in diabetes-induced renal damage,” Mediators of Inflammation, vol. 2013, Article ID 510212, 14 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. K. Taniguchi, L. Xia, H. J. Goldberg et al., “Inhibition of src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice,” Diabetes, vol. 62, no. 11, pp. 3874–3886, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. V. Kolavennu, L. Zeng, H. Peng, Y. Wang, and F. R. Danesh, “Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control,” Diabetes, vol. 57, no. 3, pp. 714–723, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. R. Komers, “Rho kinase inhibition in diabetic kidney disease,” British Journal of Clinical Pharmacology, vol. 76, no. 4, pp. 551–559, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. L. Gu, Q. Gao, L. Ni, M. Wang, and F. Shen, “Fasudil inhibits epithelial-myofibroblast transdifferentiation of human renal tubular epithelial HK-2 cells induced by high glucose,” Chemical and Pharmaceutical Bulletin, vol. 61, no. 7, pp. 688–694, 2013. View at Publisher · View at Google Scholar · View at Scopus
  113. D.-S. Jung, J. J. Li, S.-J. Kwak et al., “FR167653 inhibits fibronectin expression and apoptosis in diabetic glomeruli and in high-glucose-stimulated mesangial cells,” American Journal of Physiology—Renal Physiology, vol. 295, no. 2, pp. F595–F604, 2008. View at Publisher · View at Google Scholar · View at Scopus
  114. N. Sugiyama, M. Kohno, and T. Yokoyama, “Inhibition of the p38 MAPK pathway ameliorates renal fibrosis in an NPHP2 mouse model,” Nephrology Dialysis Transplantation, vol. 27, no. 4, pp. 1351–1358, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. S.-H. Kim, Y.-W. Jang, P. Hwang, H.-J. Kim, G.-Y. Han, and C.-W. Kim, “The reno-protective effect of a phosphoinositide 3-kinase inhibitor wortmannin on streptozotocin-induced proteinuric renal disease rats,” Experimental and Molecular Medicine, vol. 44, no. 1, pp. 45–51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. C. A. Durand, M. J. Richer, K. Brenker et al., “Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice,” Autoimmunity, vol. 46, no. 1, pp. 62–73, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. I. I. Shemesh, B. Rozen-Zvi, Y. Kalechman, U. Gafter, B. Sredni, and G. Drossopoulou, “AS101 prevents diabetic nephropathy progression and mesangial cell dysfunction: regulation of the AKT downstream pathway,” PLoS ONE, vol. 9, no. 12, 2014. View at Publisher · View at Google Scholar
  118. H. Sugimoto, V. S. LeBleu, D. Bosukonda et al., “Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis,” Nature Medicine, vol. 18, no. 3, pp. 396–404, 2012. View at Publisher · View at Google Scholar · View at Scopus
  119. F. C. Brosius III and J. C. He, “JAK inhibition and progressive kidney disease,” Current Opinion in Nephrology and Hypertension, vol. 24, no. 1, pp. 88–95, 2015. View at Google Scholar
  120. G. Ortiz-Muñoz, V. Lopez-Parra, O. Lopez-Franco et al., “Suppressors of cytokine signaling abrogate diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 21, no. 5, pp. 763–772, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. M.-L. P. Gross, A. Koch, B. Mühlbauer et al., “Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes,” Laboratory Investigation, vol. 86, no. 3, pp. 262–274, 2006. View at Publisher · View at Google Scholar · View at Scopus
  122. T. Takahashi, M. Yano, J. Minami et al., “Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy,” Diabetes Research and Clinical Practice, vol. 58, no. 2, pp. 123–129, 2002. View at Publisher · View at Google Scholar · View at Scopus
  123. S. Ogawa, T. Mori, K. Nako, T. Ishizuka, and S. Ito, “Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 2, pp. 362–368, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. J. A. Tumlin, C. M. Galphin, and B. H. Rovin, “Advanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1,” Journal of Diabetes Research, vol. 2013, Article ID 489869, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  125. R. T. Day, R. C. Cavaglieri, and D. Feliers, “Apelin retards the progression of diabetic nephropathy,” The American Journal of Physiology—Renal Physiology, vol. 304, no. 6, pp. F788–F800, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. H. Chen, J. Li, L. Jiao et al., “Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse,” The Journal of Physiology, vol. 592, part 3, pp. 505–521, 2014. View at Publisher · View at Google Scholar · View at Scopus
  127. P. Gil-Bernabe, C. N. D'Alessandro-Gabazza, M. Toda et al., “Exogenous activated protein C inhibits the progression of diabetic nephropathy,” Journal of Thrombosis and Haemostasis, vol. 10, no. 3, pp. 337–346, 2012. View at Publisher · View at Google Scholar · View at Scopus
  128. F. Barutta, F. Piscitelli, S. Pinach et al., “Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy,” Diabetes, vol. 60, no. 9, pp. 2386–2396, 2011. View at Publisher · View at Google Scholar · View at Scopus
  129. D. H. Nam, M. H. Lee, J. E. Kim et al., “Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice,” Endocrinology, vol. 153, no. 3, pp. 1387–1396, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. A. Doria, M. A. Niewczas, and P. Fiorina, “Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?” Seminars in Nephrology, vol. 32, no. 5, pp. 437–444, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. Y. Moriwaki, T. Inokuchi, A. Yamamoto et al., “Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats,” Acta Diabetologica, vol. 44, no. 4, pp. 215–218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. K. Omote, T. Gohda, M. Murakoshi et al., “Role of the TNF pathway in the progression of diabetic nephropathy in KK-Ay mice,” The American Journal of Physiology—Renal Physiology, vol. 306, no. 11, pp. F1335–F1347, 2014. View at Publisher · View at Google Scholar · View at Scopus
  133. K. Sharma, J. H. Ix, A. V. Mathew et al., “Pirfenidone for diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 22, no. 6, pp. 1144–1151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  134. H. Akahori, T. Ota, M. Torita, H. Ando, S. Kaneko, and T. Takamura, “Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression,” Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 2, pp. 514–521, 2005. View at Publisher · View at Google Scholar · View at Scopus
  135. J. Soma, K. Sato, H. Saito, and Y. Tsuchiya, “Effect of tranilast in early-stage diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 21, no. 10, pp. 2795–2799, 2006. View at Publisher · View at Google Scholar · View at Scopus
  136. F. N. Ziyadeh, “Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy,” Diabetes Research and Clinical Practice, vol. 82, supplement 1, pp. S38–S41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  137. H. Trachtman, F. C. Fervenza, D. S. Gipson et al., “A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis,” Kidney International, vol. 79, no. 11, pp. 1236–1243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  138. H. S. Jeong, K. K. Park, S. P. Kim, I. J. Choi, I. K. Lee, and H. C. Kim, “Effect of antisense TGF-β1 oligodeoxynucleotides in streptozotocin-induced diabetic rat kidney,” Journal of Korean Medical Science, vol. 19, no. 3, pp. 374–383, 2004. View at Publisher · View at Google Scholar · View at Scopus
  139. L. M. Russo, E. del Re, D. Brown, and H. Y. Lin, “Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor,” Diabetes, vol. 56, no. 2, pp. 380–388, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. G. Castoldi, C. R. T. di Gioia, C. Bombardi et al., “Renal antifibrotic effect of n-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats,” The American Journal of Nephrology, vol. 37, no. 1, pp. 64–73, 2013. View at Publisher · View at Google Scholar · View at Scopus
  141. S. G. Adler, S. Schwartz, M. E. Williams et al., “Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1420–1428, 2010. View at Publisher · View at Google Scholar · View at Scopus
  142. J. A. Moreno, S. Moreno, A. Rubio-Navarro et al., “Targeting chemokines in proteinuria-induced renal disease,” Expert Opinion on Therapeutic Targets, vol. 16, no. 8, pp. 833–845, 2012. View at Publisher · View at Google Scholar · View at Scopus
  143. M. Okamoto, M. Fuchigami, T. Suzuki, and N. Watanabe, “A novel C–C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models,” Biological and Pharmaceutical Bulletin, vol. 35, no. 11, pp. 2069–2074, 2012. View at Publisher · View at Google Scholar · View at Scopus
  144. S. J. Seok, E. S. Lee, G. T. Kim et al., “Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice,” Nephrology Dialysis Transplantation, vol. 28, no. 7, pp. 1700–1710, 2013. View at Publisher · View at Google Scholar · View at Scopus
  145. T. Sullivan, Z. Miao, D. J. Dairaghi et al., “CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice,” The American Journal of Physiology—Renal Physiology, vol. 305, no. 9, pp. F1288–F1297, 2013. View at Publisher · View at Google Scholar · View at Scopus
  146. R. J. Tan and Y. Liu, “Matrix metalloproteinases in kidney homeostasis and diseases,” The American Journal of Physiology—Renal Physiology, vol. 302, no. 11, pp. F1351–F1361, 2012. View at Publisher · View at Google Scholar · View at Scopus
  147. H. K. Aggarwal, D. Jain, P. Talapatra, R. K. Yadav, T. Gupta, and K. L. Kathuria, “Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy,” Renal Failure, vol. 32, no. 8, pp. 941–946, 2010. View at Publisher · View at Google Scholar · View at Scopus
  148. J. M. Williams, J. Zhang, P. North et al., “Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy,” The American Journal of Physiology—Renal Physiology, vol. 300, no. 4, pp. F983–F998, 2011. View at Publisher · View at Google Scholar · View at Scopus
  149. P. Trionfini, A. Benigni, and G. Remuzzi, “MicroRNAs in kidney physiology and disease,” Nature Reviews Nephrology, vol. 11, no. 1, pp. 23–33, 2014. View at Publisher · View at Google Scholar
  150. H. Wu, L. Kong, S. Zhou et al., “The role of microRNAs in diabetic nephropathy,” Journal of Diabetes Research, vol. 2014, Article ID 920134, 12 pages, 2014. View at Publisher · View at Google Scholar
  151. S. Putta, L. Lanting, G. Sun, G. Lawson, M. Kato, and R. Natarajan, “Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 23, no. 3, pp. 458–469, 2012. View at Publisher · View at Google Scholar · View at Scopus
  152. R. Ramasamy, S. F. Yan, and A. M. Schmidt, “The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes,” Vascular Pharmacology, vol. 57, no. 5-6, pp. 160–167, 2012. View at Publisher · View at Google Scholar · View at Scopus
  153. A. I. Serban, L. Stanca, O. I. Geicu, M. C. Munteanu, M. Costache, and A. Dinischiotu, “Extracellular matrix is modulated in advanced glycation end products milieu via a RAGE receptor dependent pathway boosted by transforming growth factor-β1 RAGE-β1,” Journal of Diabetes, vol. 7, no. 1, pp. 114–124, 2015. View at Publisher · View at Google Scholar
  154. A. Flyvbjerg, L. Denner, B. F. Schrijvers et al., “Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice,” Diabetes, vol. 53, no. 1, pp. 166–172, 2004. View at Publisher · View at Google Scholar · View at Scopus
  155. J. H. Kim, C. O. Hong, Y. C. Koo, S. J. Kim, and K. W. Lee, “Oral administration of ethyl acetate-soluble portion of Terminalia chebula conferring protection from streptozotocin-induced diabetic mellitus and its complications,” Biological and Pharmaceutical Bulletin, vol. 34, no. 11, pp. 1702–1709, 2011. View at Publisher · View at Google Scholar · View at Scopus
  156. W. K. Bolton, D. C. Cattran, M. E. Williams et al., “Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy,” American Journal of Nephrology, vol. 24, no. 1, pp. 32–40, 2004. View at Publisher · View at Google Scholar · View at Scopus
  157. M. E. Williams, W. K. Bolton, R. G. Khalifah, T. P. Degenhardt, R. J. Schotzinger, and J. B. McGill, “Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy,” American Journal of Nephrology, vol. 27, no. 6, pp. 605–614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  158. E. J. Lewis, T. Greene, S. Spitalewiz et al., “Pyridorin in type 2 diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 23, no. 1, pp. 131–136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  159. G. Schulman, R. Vanholder, and T. Niwa, “AST-120 for the management of progression of chronic kidney disease,” International Journal of Nephrology and Renovascular Disease, vol. 7, pp. 49–56, 2014. View at Publisher · View at Google Scholar · View at Scopus
  160. T. Sanaka, T. Akizawa, K. Koide, and S. Koshikawa, “Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy,” Therapeutic Apheresis and Dialysis, vol. 8, no. 3, pp. 232–240, 2004. View at Publisher · View at Google Scholar · View at Scopus
  161. K. Konishi, S. Nakano, S.-I. Tsuda, A. Nakagawa, T. Kigoshi, and D. Koya, “AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects,” Diabetes Research and Clinical Practice, vol. 81, no. 3, pp. 310–315, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. G. Schulman, T. Berl, G. J. Beck et al., “Randomized placebo-controlled EPPIC trials of AST-120 in CKD,” Journal of the American Society of Nephrology, 2014. View at Publisher · View at Google Scholar
  163. H. M. Wu, H. J. Sun, F. Wang, M. Yang, B. R. Dong, and G. J. Liu, “Oral adsorbents for preventing or delaying the progression of chronic kidney disease,” The Cochrane Database of Systematic Reviews, vol. 10, Article ID CD007861, 2014. View at Publisher · View at Google Scholar
  164. K. Eller, A. Kirsch, A. M. Wolf et al., “Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy,” Diabetes, vol. 60, no. 11, pp. 2954–2962, 2011. View at Publisher · View at Google Scholar · View at Scopus
  165. D. Zheng, Y. Wang, Q. Cao et al., “Transfused macrophages ameliorate pancreatic and renal injury in murine diabetes mellitus,” Nephron—Experimental Nephrology, vol. 118, no. 4, pp. e87–e99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  166. D. Patschan, K. Schwarze, E. Henze, J. U. Becker, S. Patschan, and G. A. Muller, “eEOC-mediated modulation of endothelial autophagy, senescence, and EnMT in murine diabetic nephropathy,” The American Journal of Physiology—Renal Physiology, vol. 307, no. 6, pp. F686–F694, 2014. View at Publisher · View at Google Scholar
  167. L. Vogt, C. Chiurchiu, H. Chadha-Boreham et al., “Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy,” Hypertension, vol. 55, no. 5, pp. 1206–1209, 2010. View at Publisher · View at Google Scholar · View at Scopus
  168. S. Yung, M. K. M. Chau, Q. Zhang, C. Z. Zhang, and T. M. Chan, “Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy,” PLoS ONE, vol. 8, no. 1, Article ID e54501, 2013. View at Publisher · View at Google Scholar · View at Scopus
  169. E. J. Lewis, J. B. Lewis, T. Greene et al., “Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial,” American Journal of Kidney Diseases, vol. 58, no. 5, pp. 729–736, 2011. View at Publisher · View at Google Scholar · View at Scopus
  170. D. K. Packham, R. Wolfe, A. T. Reutens et al., “Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 23, no. 1, pp. 123–130, 2012. View at Publisher · View at Google Scholar · View at Scopus